HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mineral Sunscreens Threaten Marine Ecosystems? L’Oreal Hair Care Built On Stolen IP? Personal Care News In Brief

Executive Summary

A new study published by university researchers in Spain raises questions about the impact of mineral sunscreens – specifically their release of trace metals and inorganic nutrients – on marine environments. More personal-care news.

You may also be interested in...



Oxybenzone Sunscreen Remains Live Issue As Florida Lawmakers Lay Groundwork For 2020

Florida's legislature does not reconvene until mid-January 2020, but interim committee meetings are in progress and a proposed bill to ban non-prescription sales of oxybenzone/octinoxate-containing sunscreens already has been filed for consideration in the next session.

CVS Reformulating Own-Brand Sunscreens Without Alleged Coral Killers

“CVS Pharmacy is highly attuned to our customers’ evolving needs and their desire for products that are more sustainable while still being efficacious,” says CVS Health’s George Coleman, senior vice president of merchandising. The retailer is committed to eliminating oxybenzone and octinoxate from CVS-branded sunscreens with SPFs less than 50 by the end of 2020.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel